CN116808033A - Moxidectin compound preparation and preparation method and application thereof - Google Patents
Moxidectin compound preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN116808033A CN116808033A CN202310794009.3A CN202310794009A CN116808033A CN 116808033 A CN116808033 A CN 116808033A CN 202310794009 A CN202310794009 A CN 202310794009A CN 116808033 A CN116808033 A CN 116808033A
- Authority
- CN
- China
- Prior art keywords
- moxidectin
- compound preparation
- imidacloprid
- solution
- prednisone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004816 moxidectin Drugs 0.000 title claims abstract description 135
- 238000002360 preparation method Methods 0.000 title claims abstract description 94
- -1 Moxidectin compound Chemical class 0.000 title claims abstract description 73
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims abstract description 65
- 239000005906 Imidacloprid Substances 0.000 claims abstract description 45
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229940056881 imidacloprid Drugs 0.000 claims abstract description 45
- 229960004618 prednisone Drugs 0.000 claims abstract description 41
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims abstract description 40
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 36
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 34
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 34
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000007957 coemulsifier Substances 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000077 insect repellent Substances 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 8
- 229960004063 propylene glycol Drugs 0.000 claims description 6
- 238000009924 canning Methods 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 3
- 241000282324 Felis Species 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 10
- 241000238631 Hexapoda Species 0.000 abstract description 9
- 241000238876 Acari Species 0.000 abstract description 7
- 239000004530 micro-emulsion Substances 0.000 abstract description 7
- 244000045947 parasite Species 0.000 abstract description 6
- 241000002163 Mesapamea fractilinea Species 0.000 abstract description 5
- 241001674048 Phthiraptera Species 0.000 abstract description 5
- 241000258242 Siphonaptera Species 0.000 abstract description 5
- 230000002147 killing effect Effects 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 241000242722 Cestoda Species 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 3
- 241000244206 Nematoda Species 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 48
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 241000282326 Felis catus Species 0.000 description 13
- 239000012071 phase Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 8
- 206010040880 Skin irritation Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 230000036556 skin irritation Effects 0.000 description 7
- 231100000475 skin irritation Toxicity 0.000 description 7
- 229960004217 benzyl alcohol Drugs 0.000 description 6
- 235000019445 benzyl alcohol Nutrition 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001991 scapula Anatomy 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a moxidectin compound preparation and a preparation method and application thereof, wherein the moxidectin compound preparation comprises the following components in percentage by mass: 0.4% -2.5% moxidectin, 0.4% -3.5% imidacloprid, 0.3% -1% non-prednisone, 10% -40% oil phase solvent, 20% -60% emulsifying agent, 10% -30% co-emulsifying agent and 0.05% -0.2% antioxidant. The moxidectin compound preparation provided by the invention is formed by compounding three medicinal components of moxidectin, imidacloprid and non-prednisone, and can be used for simultaneously expelling and killing various internal and external parasites such as fleas, mites, lice, ticks, nematodes, tapeworms and heartworms, and has the advantages of broad insect expelling spectrum, low toxicity and high efficiency; the moxidectin compound preparation is microemulsion, which can increase the drug permeation and improve the permeation speed; the moxidectin compound preparation adopts lower alcohol as an auxiliary emulsifier, can promote the whole transdermal transport of a drug carrying system, plays a role of a reservoir, enables the drug to be slowly released, and plays a long-acting role.
Description
Technical Field
The invention relates to the technical field of veterinary medicines, in particular to a moxidectin compound preparation and a preparation method and application thereof.
Background
With the increasing number of pets, parasitic diseases show a high tendency. And the parasitic infection not only can influence the health of pets, including host nutrition, toxin effect, tissue injury and the like, but also can cause hidden danger to the health of a feeding owner. Thus, the control of parasites is very important.
Moxidectin has a very high lipophilicity and therefore its concentration of distribution in fat is very high. Active against many internal and external parasites, especially the larval stage heartworms, is a rare anthelmintic against heartworms. The imidacloprid has the contact killing effect and is particularly suitable for being used as an external drop to expel insects to dogs. Imidacloprid inhibits cholinergic transmission of insects resulting in paralysis and death. Meanwhile, since imidacloprid has weak interaction property with the nicotinic receptor of mammal and is difficult to penetrate the blood brain barrier of mammal, it has little influence on the central nervous system of mammal and has high safety. Non-prednisone Luo Nineng compensates the short board for the expelling and killing of ticks well, so that the compound preparation has wider expelling spectrum.
While considering the efficacy of anthelmintics, we should pay more attention to the acceptability of pets. The oral insect repellent is not easy to feed; the externally applied insect repellent is convenient to use, but due to the problem of solution permeability, the skin is slow to permeate, the solution stays on the surface of the skin or hair for a long time, and pets are easier to scratch, lick, scratch, dehairing and even poisoning.
Therefore, it is necessary to develop an antiparasitic compound preparation for pets, which has wide spectrum of insect resistance, stable thermodynamics, good skin permeability and slow release.
Disclosure of Invention
In view of the defects of the prior art, the invention aims to provide a moxidectin compound preparation, a preparation method and application thereof, and aims to solve the problems of poor skin permeability, unstable thermodynamics and over-fast release of the existing antiparasitic compound preparation.
The technical scheme of the invention is as follows:
the moxidectin compound preparation comprises the following components in percentage by mass: 0.4% -2.5% moxidectin, 0.4% -3.5% imidacloprid, 0.3% -1% non-prednisone, 10% -40% oil phase solvent, 20% -60% emulsifying agent, 10% -30% co-emulsifying agent and 0.05% -0.2% antioxidant.
The moxidectin compound preparation comprises the following components in percentage by mass: 0.4% -1.4% moxidectin, 0.8% -3.5% imidacloprid, 0.3% -0.7% non-prednisone, 10% -28% oil phase solvent, 18% -52% emulsifying agent, 11% -21% co-emulsifying agent and 0.05% -0.1% antioxidant.
The moxidectin compound preparation is characterized in that the emulsifier is one or two of tween-80 and castor oil polyoxyethylene ether-40.
The moxidectin compound preparation is characterized in that the auxiliary emulsifier is one or two of 1, 2-propylene glycol and isopropanol.
The moxidectin compound preparation is characterized in that the antioxidant is one or two of dibutyl hydroxy toluene and butyl hydroxy anisole.
A method for preparing a compound preparation of moxidectin, which comprises the following steps:
sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in an oil phase solvent, and magnetically stirring until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
mixing an emulsifying agent and a coemulsifier, and magnetically stirring to obtain a solution B;
mixing the solution A and the solution B, and canning to obtain the moxidectin compound preparation.
A method for preparing a compound preparation of moxidectin, which comprises the following steps:
mixing an oil phase solvent, an emulsifier and a co-emulsifier, and magnetically stirring to obtain a solution C;
and sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in the solution C, magnetically stirring until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution D, and filling to obtain the moxidectin compound preparation.
The preparation method of the moxidectin preparation further comprises the step of adding purified water before canning.
The moxidectin compound preparation is used for preparing an insect repellent for animals.
The use wherein the animal is a canine or a feline.
The beneficial effects are that: the moxidectin compound preparation provided by the invention is formed by compounding three medicinal components of moxidectin, imidacloprid and non-prednisone, and can be used for simultaneously expelling and killing various internal and external parasites such as fleas, mites, lice, ticks, nematodes, tapeworms and heartworms, and has the advantages of broad insect expelling spectrum, low toxicity and high efficiency; the moxidectin compound preparation is microemulsion, and the lipophilic region can interact with the horny layer, so that the lipophilic medicament such as moxidectin can be directly distributed into the lipid of the horny layer to increase the medicament permeation, and the hydrophilic region can hydrate the horny layer to obviously improve the permeation rate; the moxidectin compound preparation adopts lower alcohol as an auxiliary emulsifier, can promote the whole transdermal transport of a drug carrying system, plays a role of a reservoir, enables the drug to be slowly released, and plays a long-acting role. Furthermore, the moxidectin compound preparation provided by the invention has the advantages of simple preparation process, easiness in preparation at room temperature, no special requirement on equipment and suitability for industrial production.
Drawings
Fig. 1 is a flow chart of a preparation method of a compound preparation of moxidectin.
Fig. 2 is a comparison graph of skin irritation after the moxidectin compound preparation and physiological saline are applied to guinea pigs in example 1 for 4 hours, wherein the left graph is the moxidectin compound preparation applied and the right graph is the physiological saline applied.
Fig. 3 is a graph showing the comparative results of the cumulative permeation amounts of moxidectin of the moxidectin compound formulations of example 1 and comparative example 3.
Fig. 4 is a graph showing the comparative results of the cumulative permeation amounts of moxidectin of the moxidectin compound formulations of example 2 and comparative example 4.
Fig. 5 is a graph showing the comparative results of the cumulative permeation amounts of moxidectin in the moxidectin compound formulations of example 3 and comparative example 5.
Detailed Description
The invention provides a moxidectin compound preparation, a preparation method and application thereof, and aims to make the purposes, the technical scheme and the effects of the invention clearer and more definite, and the invention is further described in detail below. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The invention provides a moxidectin compound preparation, which comprises the following components in percentage by mass: 0.4% -2.5% moxidectin, 0.4% -3.5% imidacloprid, 0.3% -1% non-prednisone, 10% -40% oil phase solvent, 20% -60% emulsifying agent, 10% -30% co-emulsifying agent and 0.05% -0.2% antioxidant.
In the invention, the moxidectin compound preparation is formed by compounding three medicinal components of moxidectin, imidacloprid and non-prednisone, can simultaneously kill various internal and external parasites such as fleas, mites, lice, ticks, nematodes, tapeworms, heartworms and the like, and has wide insect repelling spectrum, low toxicity and high efficiency; the moxidectin compound preparation is prepared into microemulsion by adding the emulsifier and the auxiliary emulsifier, and the lipophilic region can interact with the horny layer, so that the lipophilic medicament such as moxidectin can be directly distributed into the lipid of the horny layer, the medicament permeation is increased, and the hydrophilic region can be hydrated with the horny layer, so that the permeation speed is obviously improved; the moxidectin compound preparation adopts lower alcohol as a co-emulsifier and combines with an oil phase solvent, so that the moxidectin compound preparation can promote the whole transdermal transport of a drug carrying system, plays a role of a reservoir, enables a drug to be slowly released and plays a long-acting role.
In some embodiments, the moxidectin compound preparation comprises, in mass percent: 0.4% -1.4% moxidectin, 0.8% -3.5% imidacloprid, 0.3% -0.7% non-prednisone, 10% -28% oil phase solvent, 18% -52% emulsifying agent, 11% -21% co-emulsifying agent and 0.05% -0.1% antioxidant. In the embodiment, the moxidectin compound preparation prepared by optimizing the components has better insect repellent effect, better drug permeation and more stable thermodynamics.
In some embodiments, the emulsifier is one or two of tween-80 and castor oil polyoxyethylene ether-40, but is not limited thereto; the auxiliary emulsifier is one or two of 1, 2-propylene glycol and isopropanol, but is not limited to the above.
In some embodiments, the antioxidant is one or both of dibutyl hydroxy toluene (BHT), butyl Hydroxy Anisole (BHA), but is not limited thereto.
In some embodiments, there is also provided a method for preparing a compound moxidectin preparation, as shown in fig. 1, comprising the steps of:
s10, sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in an oil phase solvent, and magnetically stirring until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
s20, mixing an emulsifying agent and a coemulsifier, and magnetically stirring to obtain a solution B;
s30, mixing the solution A with the solution B, and canning to obtain the moxidectin compound preparation.
The moxidectin compound preparation provided by the invention has the advantages of simple preparation process, easiness in preparation at room temperature, no special requirement on equipment and suitability for industrial production.
In another embodiment, there is also provided another method for preparing a compound preparation of moxidectin, comprising the steps of: mixing an oil phase solvent, an emulsifier and a co-emulsifier, and magnetically stirring to obtain a solution C; and sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in the solution C, magnetically stirring until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution D, and filling to obtain the moxidectin compound preparation.
In some embodiments, the method further comprises the step of adding purified water before canning, wherein the concentration and physical state of the moxidectin compound preparation are adjusted by adding purified water.
In some embodiments, the invention also provides an application of the moxidectin compound preparation, wherein the moxidectin compound preparation is used for preparing an insect repellent for animals. In this embodiment, the animal is a canine or a feline.
The invention is further illustrated by the following examples:
example 1
The invention provides a moxidectin compound preparation, which comprises the following raw materials in percentage by mass (g): moxidectin 1%, imidacloprid 2%, non-prednisone 0.5%, benzyl alcohol 22%, EL-40 41.6%,1, 2-propanediol 20.35%, BHT 0.05% and purified water 12.5%.
In yet another aspect of the present embodiment, a method for preparing a compound preparation of corresponding moxidectin is provided, including the following steps:
a. sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in benzyl alcohol, magnetically stirring at a rotating speed of 500r/min until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
b. mixing an emulsifier and a coemulsifier according to a certain proportion, magnetically stirring for 10min at a rotating speed of 500r/min to obtain a solution B;
c. mixing the solution A and the solution B, adding purified water, changing the solution from turbidity to clarification, and filling to finish.
The using method comprises the following steps: based on the product, the external use is as follows: the dosage is 0.2mL/kg once, and the administration is once a month; the product can be dropped onto skin between two scapula on animal back to buttock to prevent animal licking. Animals other than and not only dogs and cats below their age of february are forbidden, and are carefully used for dogs and cats during pregnancy and lactation.
Example 2
The invention provides a moxidectin compound preparation, which comprises the following raw materials in percentage by mass (g): moxidectin 1.4%, imidacloprid 2.85%, non-prednisone 0.6%, benzyl alcohol 28%, EL-40%, isopropanol 17.1%, BHT 0.05% and purified water 0.
In still another aspect of the present invention, a method for preparing a compound moxidectin preparation is provided, comprising the following steps:
a. sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in benzyl alcohol, magnetically stirring at a rotating speed of 500r/min until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
b. mixing an emulsifier and a coemulsifier according to a certain proportion, magnetically stirring for 10min at a rotating speed of 500r/min to obtain a solution B;
c. mixing the solution A and the solution B, and filling to finish.
The using method comprises the following steps: based on the product, the external use is as follows: the dosage is 0.15mL/kg once, and the administration is once a month. The product can be dropped on the skin between the two scapula of the back of the animal to the buttock to prevent the animal from licking; animals other than and not only dogs and cats below their age of february are forbidden, and are carefully used for dogs and cats during pregnancy and lactation.
Example 3
The invention provides a moxidectin compound preparation, which comprises the following raw materials in percentage by mass (g): moxidectin 0.4%, imidacloprid 0.8%, non-prednisone 0.3%, benzyl alcohol 10.9%, tween-80 25%,1, 2-propanediol 12.5%, BHT 0.1% and purified water 50%.
In still another aspect of the present invention, a method for preparing a compound moxidectin preparation is provided, comprising the following steps:
a. sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in benzyl alcohol, magnetically stirring at a rotating speed of 500r/min until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
b. mixing an emulsifier and a coemulsifier according to a certain proportion, magnetically stirring for 10min at a rotating speed of 500r/min to obtain a solution B;
c. mixing the solution A with the solution B, and filling to obtain a solution C.
d. The solution C was then added with an appropriate amount of water and shaken to obtain a clear solution D from cloudiness.
The using method comprises the following steps: based on the product, the medicine is prepared for external use at present: the amount is 0.4mL/kg once, and 1-2 times per week when severe. The product can be sprayed on the parts with more ectoparasites to prevent animals from licking; animals other than and not only dogs and cats below their age of february are forbidden, and are carefully used for dogs and cats during pregnancy and lactation.
Example 4
The invention provides a moxidectin compound preparation, which comprises the following raw materials in percentage by mass (g): moxidectin 1.3%, imidacloprid 3.5%, non-prednisone 0.7%, benzyl alcohol 25%, EL-40% 52%, isopropanol 17.35%, BHT 0.05% and purified water 0.
In still another aspect of the present invention, a method for preparing a compound moxidectin preparation is provided, comprising the following steps:
a. mixing benzyl alcohol, an emulsifying agent and a coemulsifier according to a certain proportion, magnetically stirring for 10min at 40 ℃ and rotating at 500r/min to obtain a solution A;
b. sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in the solution A, magnetically stirring at a rotating speed of 500r/min until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution B;
the using method comprises the following steps: based on the product, the external use is as follows: the dosage is 0.1mL/kg once, and the administration is once a month. The product can be dropped on the skin between the two scapula of the back of the animal to the buttock to prevent the animal from licking; animals other than and not only dogs and cats below their age of february are forbidden, and are carefully used for dogs and cats during pregnancy and lactation.
Comparative example 1
The invention provides a moxidectin compound preparation, which comprises the following raw materials in percentage by mass (g): moxidectin 0.4%, imidacloprid 0.8%, non-prednisone 0.3%, benzyl alcohol 23.45%, tween-80 25%,1, 2-propanediol 25%, BHT 0.05% and purified water 25%.
In still another aspect of the present invention, a method for preparing a compound moxidectin preparation is provided, comprising the following steps:
a. sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in benzyl alcohol, magnetically stirring at a rotating speed of 500r/min until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
b. mixing an emulsifier and a coemulsifier according to a certain proportion, magnetically stirring for 10min at a rotating speed of 500r/min to obtain a solution B;
c. mixing the solution A with the solution B, and filling to obtain a solution C;
d. purified water was added to solution C and shaken to give solution D.
Comparative example 2
The invention provides a moxidectin compound preparation, which comprises the following raw materials in percentage by mass (g): moxidectin 0.7%, imidacloprid 1.8%, non-prednisone 0.3%, benzyl alcohol 10%, EL-40.65%, isopropanol 8%, BHT 0.05%
And (3) 62.5% of purified water.
In still another aspect of the present invention, a method for preparing a compound moxidectin preparation is provided, comprising the following steps:
a. sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in benzyl alcohol, magnetically stirring at a rotating speed of 500r/min until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
b. mixing an emulsifier and a coemulsifier according to a certain proportion, magnetically stirring for 10min at a rotating speed of 500r/min to obtain a solution B;
c. mixing the solution A and the solution B, adding purified water, changing the solution from turbidity to clarification, and filling to finish.
Specific components and contents of the moxidectin compound preparation in the above examples 1 to 4 and comparative examples 1 to 2 are shown in table 1.
Table 1 specific ingredients and contents of moxidectin compound formulation
The moxidectin compound preparation prepared in examples 1 to 4 and comparative examples 1 and 2 is used for carrying out stability test, and the preparation with better stability is initially screened out for carrying out skin local irritation test, in-vitro skin permeability test and in-vitro insect repellent effect test of dogs and cats.
Test example 1
Stability test:
the samples of examples 1 to 4 and the samples of comparative examples 1 and 2 were centrifuged at 3000r/min for 5min, and the liquid layer and the sedimentation were observed, and the results are shown in Table 2.
Table 2 sample centrifugation results
Samples of examples 1 to 4 and samples of comparative examples 1 and 2 were stored at 25℃and 60℃respectively, taken out at 0d, 5d and 10d, left standing at room temperature for 3 hours, and then observed for turbidity, delamination and precipitation, and the results are shown in Table 3.
TABLE 3 results of sample standing
As can be seen from the results in tables 2-3, the moxidectin compound preparations prepared in examples 1-4 are relatively stable, and a small amount of imidacloprid is easy to separate out after long-term setting in example 3, so that the moxidectin compound preparation is suitable for being prepared at present; in the compound preparation of moxidectin in comparative example 1, microemulsion cannot be formed due to improper proportion of oil phase, water phase, emulsifier and co-emulsifier; the moxidectin compound preparation in comparative example 2 can form microemulsion, but the high-proportion imidacloprid and the aqueous phase solvent have poor compatibility and separate out a large amount of crystals, so the compound preparation is eliminated.
Test example 2
Skin irritation experiments:
skin irritation tests were performed on the samples of examples 1 to 4 with reference to the pharmaceutical non-clinical study quality control Specification and the guidelines for the study of chemical drug irritation, allergy and hemolysis.
And selecting guinea pigs with the weight of more than or equal to 200g, wherein the number of animals in each group is 4, and the female animals and the male animals are half. Physiological saline is used for comparison, and a self-comparison method of the left side and the right side of the homozygote is adopted. Dehairing was performed on both sides of the back 24 hours prior to the test. The dehairing range is 3cm multiplied by 3cm on the left and right. Damaged skin is eliminated.
0.5mL of the test object is directly coated on the skin with one side dehaired, then covered by two layers of gauze (2.5 cm multiplied by 2.5 cm) and a layer of preservative film, and then fixed by gauze and bandage; the other side was coated with 0.5mL of physiological saline as a control. The application time is 1h. After the application, the test substance was removed and the administration site was cleaned with warm water. The skin reaction was observed under natural light. The skin erythema and edema were scored according to the scoring criteria given in tables 4 to 5, and the results are shown in table 6 and fig. 2, and fig. 2 is a graph showing the comparison of skin irritation after the moxidectin compound preparation and physiological saline for 4 hours in example 1 were applied to guinea pigs, wherein the left graph is the moxidectin compound preparation, and the right graph is the physiological saline.
TABLE 4 skin irritation response scoring criteria
TABLE 5 skin irritation intensity evaluation criteria
| Evaluation | Score value |
| No irritation | 0-0.49 |
| Mild irritation | 0.5-2.99 |
| Moderate irritation | 3.0-5.99 |
| Strong irritation | 6.0-8.0 |
TABLE 6 skin irritation response scoring results
As can be seen from the results of Table 6 and FIG. 2, the moxidectin compound formulations prepared in examples 1 to 4 were not irritating to the skin of guinea pigs.
Test example 3
In vitro skin penetration test:
collecting Kunming mice, killing the mice by neck breakage, peeling the skin of chest and abdomen, cleaning the hair and subcutaneous tissue by a shaver and a surgical blade, and eliminating skin damage. Then normal temperature normal saline is cleaned, and the mixture is placed in normal saline for preservation at 4 ℃ and used up within 4 days. The skin should be warmed to room temperature before use.
Examples 1-3 were selected for testing, and a comparative recipe having a moxidec Ding Zhiliang fraction identical to that of examples 1-3, respectively, was additionally prepared as comparative examples 3-5, as shown in Table 7.
Table 7 moxidectin Compound formulation of comparative examples 3-5
The test was performed using a transdermal diffusion device. The skin is pre-immobilized, the skin contacts the receiving pool subcutaneously, and the epidermis contacts the supply pool. The instrument is rotated and adjusted to 200r/min, the temperature is 37+/-0.2 ℃, 1mL of each of 6 prescriptions is respectively taken in a supply tank, and the upper end of the administration is sealed by a preservative film. After starting the apparatus, 4mL of the receiving pool liquid was withdrawn every 1, 3, 6, 9, 12, 16, 21, 28h, and 4mL of the receiving liquid (30% ethanol-physiological saline solution) was supplemented. After the extracted receiving solution was filtered with a 0.2nm filter, the moxidectin concentration was measured by HPLC, and the results are shown in Table 8 and FIGS. 3 to 5.
TABLE 8 cumulative osmotic amount of moxidectin
As can be seen from the data in table 8 and fig. 3-5, the self-microemulsions of examples 1-3 had a cumulative moxidectin permeation greater than the corresponding comparative example group over 28 hours at the same mass fraction moxidectin content, and the permeation rate was relatively gentle.
Test example 4
In vitro insect repellent test for dogs and cats
The anti-lice and flea effects of the moxidectin formulated self-microemulsions prepared in accordance with the present invention are described below in connection with specific experiments.
Condition of selection: adult breeds are not limited, the weight of dogs is more than or equal to 5kg, the weight of cats is more than or equal to 2.5kg, and the number of on-body lice and fleas is not less than 5.
The experimental method comprises the following steps: the 40 sick dogs were randomly divided into 4 groups, and moxidectin compound preparations in examples 1 to 4 were used, respectively; the 40 diseased cats were randomly divided into 4 groups and moxidectin compound preparations of examples 1 to 4 were used, respectively.
The experimental method comprises the following steps: the teeth comb is used to comb along the longest muscles of the back and waist (i.e. two sides of the spine), the head and abdomen, and count the total number of lice and fleas. Lice and flea counts were observed at 0d (pre-dose), 1d, 3d, 7d and 28d, and the results are shown in Table 9.
Evaluation of results: and (3) curing: the clinical symptoms disappear, and the insect reduction rate is more than or equal to 90%; the effective rate is more than or equal to 90 percent, and the insect reduction rate is more than or equal to 60 percent; the pest-reducing rate is less than 60 percent.
Usage and dosage: according to the above description.
The formula:
TABLE 9 results of insect reduction rates in dogs and cats following drug administration
The relevant clinical symptoms of the experimental animals are observed and recorded daily, and the data in the table 9 show that 1d after the administration, the insect-reducing effect of the example 3 is most obvious; 3d after the medicine is taken, the symptoms of the parasitic infection are greatly improved, and most of the effects of clinical cure can be achieved; the number of 7d parasites was essentially zero.
It is to be understood that the invention is not limited in its application to the examples described above, but is capable of modification and variation in light of the above teachings by those skilled in the art, and that all such modifications and variations are intended to be included within the scope of the appended claims.
Claims (10)
1. The moxidectin compound preparation is characterized by comprising the following components in percentage by mass: 0.4% -2.5% moxidectin, 0.4% -3.5% imidacloprid, 0.3% -1% non-prednisone, 10% -40% oil phase solvent, 20% -60% emulsifying agent, 10% -30% co-emulsifying agent and 0.05% -0.2% antioxidant.
2. The moxidectin compound preparation according to claim 1, characterized in that the moxidectin compound preparation comprises, in mass percent: 0.4% -1.4% moxidectin, 0.8% -3.5% imidacloprid, 0.3% -0.7% non-prednisone, 10% -28% oil phase solvent, 18% -52% emulsifying agent, 11% -21% co-emulsifying agent and 0.05% -0.1% antioxidant.
3. The moxidectin compound preparation according to claim 1 or 2, characterized in that the emulsifier is one or two of tween-80 and castor oil polyoxyethylene ether-40.
4. The moxidectin compound preparation according to claim 1 or 2, characterized in that the co-emulsifier is one or two of 1, 2-propanediol and isopropanol.
5. The moxidectin compound preparation according to claim 1 or 2, characterized in that the antioxidant is one or two of dibutyl hydroxy toluene and butyl hydroxy anisole.
6. A process for the preparation of a moxidectin compound formulation as claimed in any one of claims 1 to 5, comprising the steps of:
sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in an oil phase solvent, and magnetically stirring until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution A;
mixing an emulsifying agent and a coemulsifier, and magnetically stirring to obtain a solution B;
mixing the solution A and the solution B, and canning to obtain the moxidectin compound preparation.
7. A process for the preparation of a moxidectin compound formulation as claimed in any one of claims 1 to 5, comprising the steps of:
mixing an oil phase solvent, an emulsifier and a co-emulsifier, and magnetically stirring to obtain a solution C;
and sequentially dissolving moxidectin, imidacloprid, non-prednisone and an antioxidant in the solution C, magnetically stirring until the moxidectin, the imidacloprid, the non-prednisone and the antioxidant are completely dissolved to obtain a solution D, and filling to obtain the moxidectin compound preparation.
8. The method for preparing moxidectin complex formulation of claim 7, further comprising the step of adding purified water prior to filling.
9. The application of the moxidectin compound preparation is characterized in that the moxidectin compound preparation in any one of claims 1-5 is used for preparing an insect repellent for animals.
10. The use according to claim 9, wherein the animal is a canine or a feline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310794009.3A CN116808033A (en) | 2023-06-29 | 2023-06-29 | Moxidectin compound preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310794009.3A CN116808033A (en) | 2023-06-29 | 2023-06-29 | Moxidectin compound preparation and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116808033A true CN116808033A (en) | 2023-09-29 |
Family
ID=88142722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310794009.3A Pending CN116808033A (en) | 2023-06-29 | 2023-06-29 | Moxidectin compound preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116808033A (en) |
-
2023
- 2023-06-29 CN CN202310794009.3A patent/CN116808033A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3507799B2 (en) | Antiparasitic formulation | |
| CN105853454A (en) | Broad-spectrum antiparasitic drug nano-emulsion and preparation method thereof | |
| CN106511267A (en) | Compound moxidectin drops as well as preparation method and application thereof | |
| CN114259464B (en) | Compound moxidectin external drop | |
| BG107038A (en) | Composition against endopa gel | |
| CN113616653A (en) | Imidacloprid-containing compound preparation with good low-temperature stability and preparation method thereof | |
| DE102005009515A1 (en) | A process for preparing a preparation of a DMSO-containing solid silicone oil emulsion for binding reactive oxygen compounds in the body of humans and animals | |
| DE60018200T2 (en) | USE OF PULLEOMUTILINE DERIVATIVES FOR THE TRANSDERMAL TREATMENT OF BACTERIAL DISEASES | |
| CN111514157A (en) | Application of composition in preparation of veterinary anti-parasitic drug, veterinary anti-parasitic transdermal solution and preparation method thereof | |
| CN116808033A (en) | Moxidectin compound preparation and preparation method and application thereof | |
| KR101326428B1 (en) | High dosage doramectin formulation | |
| RU1836084C (en) | A way of obtaining the preparation for therapy of parasite diseases in animals | |
| Geurden et al. | alpaca herd | |
| CN106692171B (en) | Compound selamectin external drop for pets as well as method and application thereof | |
| DE69918165T2 (en) | DORAMECTINFORMULIERUNGEN | |
| JP2006508957A (en) | Combined products for controlling pests | |
| RU2251421C2 (en) | Antiparasitic preparation for needle-free injection | |
| CN112972437B (en) | Long-acting external preparation containing iodonitrophenol and preparation method and application thereof | |
| CN115671040B (en) | External preparation for controlling animal parasite infection | |
| CN111568901B (en) | Animal external parasite control agent and preparation method thereof | |
| CN116407501B (en) | Moxidec Ding Bichong-line drop and preparation method and application thereof | |
| HU198843B (en) | Process for producing veterinary compositions with disinfecting and antiinflammatory action, comprising natural active ingredient and suitable particularly for treating mastitis | |
| Rahman et al. | Comparative efficacy of Neem leaves and Ivermectin (Ivomec®) against ectoparasites in calves | |
| CN112641723B (en) | Pharmaceutical composition for treating otoacarid and preparation method thereof | |
| AU2017200250B2 (en) | A Tick Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |